Open-label prophylaxis data supporting the long-term safety profile and sustained benefits of deucrictibant, as well as clinical validation data ...

The ongoing global Phase 2b REZOLVE-AD study (NCT06136741) enrolled 393 patients with moderate-to-severe atopic dermatitis who had not previously received treatment with biologic or JAK inhibitor ...

The abstract, titled, "A Phase 2a Randomized, Double-Blind, Controlled Trial of the Efficacy and Safety of an Intravenous (IV) Bacteriophage Cocktail (AP-SA02) vs. Placebo in Combination with Best ...

New data from OASIS 4 on oral semaglutide 25 mg to reveal insights on cardiometabolic health among adults with obesity or overweight Additional trial insights into impact on ability to do everyday ...

CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, ...

Presenting Author: Aftab Ala, MBBS, M.D., FRCP, Ph.D. The abstract is currently available on the conference website, and the materials for the oral presentation will be available at www.monopartx.com ...

CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Neutrolis Inc., a clinical-stage biotech company focused on targeting Neutrophil Extracellular Traps (NETs) to revolutionize the treatment of ...

CAMBRIDGE, United Kingdom and NEW YORK, October 13, 2025 - Artios Pharma Limited ("Artios”), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage ...

Professor Philip Molyneaux will give an oral presentation on the key efficacy and safety results from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with ...

Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting WATERTOWN, Mass., Oct. 06, ...

A novel bispecific T cell engager for the treatment of solid tumors that express DARKFOX TM, a previously undiscovered antigen derived from an alternative open reading frame of FOXM1. Abstract number: ...

Pfizer Inc. is acquiring Metsera, Inc. for $47.5/share plus up to $22.5/share in CVRs, aiming to re-enter the obesity drug market. MTSR's pipeline includes promising GLP-1 and amylin analog candidates ...